Ascites Fluid Removal Devices Market

The global ascites fluid removal devices market is projected to total USD 0.78 billion in 2026, advancing to USD 1.77 billion by 2036, achieving a CAGR of 8.5%. This growth is driven by the rising global burden of advanced liver disease and cancers that cause fluid accumulation, coupled with a shift towards more controlled and efficient drainage methods.

Summary of Ascites Fluid Removal Devices Market

• Market Snapshot

  • Global ascites fluid removal devices market revenue stood at USD 0.78 billion in 2026 and is forecast to reach USD 1.77 billion by 2036.

  • Ata8.5% CAGR from 2026 to 2036, this market is set to expand ~2.3x in value, adding USD 0.99 billion in absolute opportunity.

  • Growth is driven by the rising global burden of advanced liver diseases and cancers associated with fluid accumulation, increasing the need for effective and controlled drainage solutions in clinical practice.

  • The market iswitnessinga transition toward automated and controlled fluid removal systems, improving procedural safety, efficiency, and patient comfort compared to conventional drainage approaches.

• Demand and Growth Drivers

  • Rising prevalence of liver cirrhosis, cancer, and chronic diseases leading to ascites is expanding the patient pool requiring repeated fluid removal procedures.

  • Increasing adoption of controlled and automated drainage systems is improving safety by reducing complications such as hypotension and infection, driving preference over manual techniques.

  • Growing focus on reducing hospital readmissions and improving long-term fluid management is supporting the adoption of advanced ascites drainage devices across healthcare systems.

  • Technological advancements enabling integrated monitoring, controlled flow rates, and safer fluid extraction are enhancing clinical outcomes and physician confidence.

  • Expansion of outpatient and home-based care models is further accelerating demand for efficient and patient-friendly fluid removal solutions.

• Product and Segment View

  • Automated paracentesis systems hold 54.6% of device type share in 2026,emergingas the leading segment, driven by their ability to provide controlled, measured fluid removal with enhanced safety and monitoring capabilities.

  • Liver cirrhosis accounts for 64.1% of treatment segment share in 2026, positioning it as the dominant application area, reflecting the high incidence of ascites associated with chronic liver disease.

  • Hospitalsrepresent67.2% of end-use share in 2026, supported by their role in managing complex cases and performing high volumes of fluid removal procedures.

  • Manual drainage kits and closed-loop systems complement the market, serving specific procedural and care-setting requirements across hospitals and outpatient environments.

• Geography and Competitive Outlook

  • India (12.3% CAGR) and China (12.1%) are the fastest-growing markets, driven by improving diagnostic rates, expanding healthcare infrastructure, and increasing access to interventional therapies.

  • United States (11.0% CAGR) continues to be a major market supported byestablishedhealthcare systems and high adoption of advanced medical devices.

  • United Kingdom (9.3%) and Germany (9.1%)demonstratesteady growth, supported by structured clinical pathways and rising prevalence of chronic diseases.

  • Key companies active in this market include Sequana Medical, Becton, Dickinson & Company, Cardinal Health,AngioDynamics, and Cook Medical.

Ascites Fluid Removal Devices Market — At a Glance

The market is characterized by the significant adoption of automated paracentesis systems, which hold a 54.6% share, primarily used for treating liver cirrhosis, an application constituting 64.1% of the market. Hospitals are the central end-user, accounting for 67.2% of demand, as they manage the most complex cases.

Geographically, India and China show the highest projected growth with CAGRs of 12.3% and 12.1% respectively, driven by improving diagnostic rates and expanding access to interventional therapies. The USA follows at 11.0%, with the UK and Germany growing at 9.3 and 9.1%.

Demand is fundamentally linked to the growing prevalence of non-alcoholic fatty liver disease, the need to reduce hospital readmissions through effective fluid management, and technological advancements that make procedures safer and suitable for outpatient or home care settings.

By Device Type, Which Technology is Improving Procedural Safety and Efficiency?

Automated paracentesis systems command a dominant 54.6 % share. This preference is driven by their ability to provide controlled, measured fluid removal with integrated monitoring of vital signs, significantly reducing the risk of complications like hypotension compared to manual techniques.

Their use streamlines workflow in busy hospital units and improves patient comfort, making them the standard of care in advanced healthcare settings for managing recurrent, large-volume ascites.

By Treatment, Which Underlying Condition is the Primary Clinical Driver?

Liver cirrhosis is the leading treatment segment with a 64.1 % share. Ascites is the most common decompensating event in cirrhosis, marking a pivotal point in disease progression. The high prevalence of cirrhosis globally, driven by hepatitis, alcohol-related liver disease, and NAFLD, creates a large and recurring patient population requiring repeated therapeutic paracentesis, establishing it as the core, volume-driven indication for fluid removal devices.

By End User, Where is the Highest Acuity Care Provided?

Hospitals constitute the primary end-user segment at 67.2 %. The management of symptomatic ascites, especially in unstable patients or those with associated complications like infection or kidney dysfunction, requires the multidisciplinary resources and immediate intervention capabilities only available in a hospital setting. This centralizes the procedure and the associated device utilization within acute care facilities.

The paramount driver is the escalating global epidemic of metabolic dysfunction-associated steatotic liver disease, which is increasing the incidence of cirrhosis and its complications, including ascites. A significant restraint is the high cost of advanced automated systems and implantable pumps, which limits their adoption in cost-sensitive healthcare systems and lower-resource settings, perpetuating reliance on basic manual kits.

A major opportunity lies in the development of simplified, patient-friendly closed-loop systems designed for safe use in home or ambulatory care settings, which could drastically reduce hospitalizations and improve quality of life. The dominant trend is the integration of telehealth and remote monitoring capabilities into device platforms, allowing clinicians to track patient fluid status and device performance remotely, enabling more proactive and personalized ascites management.

How does the USA's Focus on Reducing Hospital Readmissions Influence the Market?

The USA's strong 11.0% CAGR is propelled by healthcare economics that penalize hospitals for preventable readmissions, making efficient outpatient management of chronic conditions like ascites a financial imperative.

This drives adoption of advanced automated systems that enable safe, high-volume paracentesis in specialized clinics or even home settings. Growth is further fueled by a high prevalence of NAFLD-related cirrhosis and robust reimbursement pathways for both the procedure and the newer implantable pump technologies, encouraging technological adoption.

What Strategic Healthcare Priorities Underpin China's High Growth Rate?

China's robust 12.1% CAGR is linked to its national efforts to improve diagnosis and management of chronic liver disease, a major public health burden. Growth is driven by the rapid expansion of hepatology and interventional radiology departments in urban tertiary hospitals, which are adopting standard-of-care technologies.

The domestic medical device industry is actively developing more affordable paracentesis systems, aiming to capture the vast mid-tier hospital market and support the decentralization of care.

How is India's Evolving Healthcare Infrastructure Shaping Adoption Trends?

India's leading 12.3% CAGR is fueled by a dual-track healthcare expansion. In major private hospital chains, there is growing investment in advanced hepatology units equipped with automated paracentesis systems to attract patients.

Increasing awareness and diagnosis of liver disease in the public health system is creating a massive base-level demand for manual and basic automated drainage kits. This bifurcation creates opportunities for a wide range of device sophistication and price points.

What Factors Characterize the UK's Protocol-Driven and Cost-Conscious Market?

The UK's 9.3% growth is defined by the National Health Service's protocol-driven approach and focus on health technology assessment. Adoption of new devices is carefully evaluated for cost-effectiveness within integrated care pathways for liver disease.

Growth is steady, driven by the need to manage a growing cirrhosis population efficiently within budget constraints, favoring technologies that demonstrably reduce total cost of care by preventing complications or enabling community-based management.

How does Germany's Specialist-Driven System Guide Technology Uptake?

Germany's 9.1% CAGR reflects its specialist-centric healthcare model. Adoption is led by university hospitals and specialized gastroenterology/hepatology centers where physicians drive technology choices based on clinical evidence.

The market is characterized by a willingness to invest in high-end, innovative systems like implantable pumps for selected patients, supported by the country's robust reimbursement system for inpatient and outpatient specialist care.

The competitive landscape features a mix of pioneering medical technology firms focused on chronic disease management and large, established medtech corporations with broad vascular access and interventional portfolios.

Innovation leaders like Sequana Medical compete by developing and commercializing novel implantable pump systems that represent a paradigm shift from periodic drainage to continuous fluid management.

Larger players such as BD and Cardinal Health leverage their extensive distribution networks and expertise in single-use, sterile procedural kits to dominate the market for manual and automated paracentesis systems used in hospitals.

Success in this market is determined by generating robust clinical data to secure reimbursement, demonstrating clear improvements in patient outcomes and cost-of-care, and building strong advocacy among hepatologists and interventional radiologists who are the key prescribers of these therapies.

• Sequana Medical
• Becton, Dickinson & Company (BD)
• Cardinal Health
• AngioDynamics
• Cook Medical
• Others

• American Association for the Study of Liver Diseases. (2025). Practice Guidance on the Management of Ascites Due to Cirrhosis. Hepatology.
• European Association for the Study of the Liver. (2024). EASL Clinical Practice Guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Journal of Hepatology.
• Ginès, P., & Solà, E. (2024). Current and future therapies for ascites in cirrhosis. Nature Reviews Gastroenterology & Hepatology, 21(4), 235-250.
• National Institute for Health and Care Excellence. (2025). Technology Appraisal Guidance: Automated low-flow ascites pumps. NICE.
• Runyon, B. A. (2024). Management of Adult Patients with Ascites Due to Cirrhosis: Update 2024. AASLD.

• Device Type :

  • Automated Paracentesis Systems
  • Manual Drainage Kits
  • Closed-Loop Systems

• Treatment :

  • Liver Cirrhosis
  • Oncology-Related Ascites
  • Others

• End User :

  • Hospitals
  • Home Care
  • Clinics

• Region :

  • North America

    • USA
    • Canada

  • Latin America

    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America

  • Western Europe

    • Germany
    • France
    • Italy
    • Spain
    • UK
    • BENELUX
    • Rest of Western Europe

  • Eastern Europe

    • Russia
    • Poland
    • Czech Republic
    • Rest of Eastern Europe

  • East Asia

    • China
    • Japan
    • South Korea
    • Rest of East Asia

  • South Asia & Pacific

    • India
    • ASEAN
    • Australia
    • Rest of South Asia & Pacific

  • MEA

    • GCC Countries
    • South Africa
    • Turkiye
    • Rest of MEA